Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05583149
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:32.498154+00:00
Published At
2026-01-29T00:00:00+00:00
Record Updated At
2026-01-29
Results Posted At
2026-01-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Refractory Aggressive B-cell Lymphomas", "Refractory B-Cell Non-Hodgkin Lymphoma", "Aggressive B-cell NHL", "Diffuse Large B-cell Lymphoma (DLBCL)", "De Novo or Transformed Indolent B-cell Lymphoma", "DLBCL, Nos Genetic Subtypes", "T Cell/Histiocyte-rich Large B-cell Lymphoma", "EBV-Positive DLBCL, Nos", "Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)", "High-Grade B-Cell Lymphoma, Nos", "C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-29"
protocolSection.identificationModule.nctId
"NCT05583149"
protocolSection.identificationModule.officialTitle
"A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2026-01-29"

Study condition terms

  • Refractory Aggressive B-cell Lymphomas (protocolSection.conditionsModule.conditions)
  • Refractory B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Aggressive B-cell NHL (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
  • De Novo or Transformed Indolent B-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • DLBCL, Nos Genetic Subtypes (protocolSection.conditionsModule.conditions)
  • T Cell/Histiocyte-rich Large B-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • EBV-Positive DLBCL, Nos (protocolSection.conditionsModule.conditions)
  • Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL) (protocolSection.conditionsModule.conditions)
  • High-Grade B-Cell Lymphoma, Nos (protocolSection.conditionsModule.conditions)
  • C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Grade 3b Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.